NEAT 022 (SSAT060)


An open label study examining the efficacy and cardiovascular risk of immediate versus deferred switch from a boosted PI to dolutegravir (DTG) in HIV infected patients with stable virological suppression


Phase: IV


Indication: HIV-1 patients on PI/r plus two NRTIs


Countries:  UK, France, Germany, Belgium, Spain, Italy


Status: Closed

Administrative office: NEAT ID Foundation, 27 Old Gloucester Street, London WC1N 3AX, UK



Registered address: PL 709  Rue Haute 322, 1000 Brussels, Belgium

©NEAT ID 2019